AbbVievsPhathom Pharmaceuticals

ABBV and PHAT stock compared: price, dividend, valuation and results, from SEC filings.

PHAT

Phathom Pharmaceuticals, Inc.

$6.06

Value $478M

-2.73%
PHAT's page

AbbVie (ABBV) has a market value of $522B and Phathom Pharmaceuticals (PHAT) $478M. Over the last year, with dividends, ABBV moved +30.3% and PHAT -58.5%. Dividend yield: ABBV 2.35%, PHAT none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$522B

    PHAT$478M

    ABBV is 1,092 times PHAT

  • Revenue, 12 months

    ABBV$66.0B

    PHAT$275M

    ABBV is 240 times PHAT

  • Net income, 12 months

    ABBV$10.3B

    PHAT-$83M

  • Operating margin

    ABBV32.2%

    PHAT-9.3%

    41.5 points apart

  • ROIC

    ABBV25.7%

    PHAT–

  • P/E

    ABBV50.7

    PHAT–

  • Dividend yield

    ABBV2.4%

    PHAT0.0%

    2.4 points apart

  • 5-year return

    ABBV+201.5%

    PHAT-72.2%

    273.7 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+201.5%

PHAT-72.2%

010020030020222023202420252026
Returns by period
PeriodABBVWith dividendsPHATWith dividends
1 year since November 12, 2025+30.3%Price +26.5%-58.5%Price -58.5%
3 years since November 13, 2023+135.3%+33.0% a yearPrice +112.8%-15.2%-5.4% a yearPrice -15.2%
5 years since November 12, 2021+201.5%+24.7% a yearPrice +152.2%-72.2%-22.6% a yearPrice -72.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbViePHATPhathom Pharmaceuticals

Valuation

ABBVPHAT
Valuation
Price$295.03$6.06
Market value$522B$478M
Enterprise value (EV)$592B–
P/E50.7–
P/E, 5-year median57.0–
P/B––
EV/EBIT27.9–
Free cash flow yield3.6%–

Results and growth

ABBVPHAT
Results and growth
Revenue, 12 months$66.0B$275M
Net income, 12 months$10.3B-$83M
Free cash flow, 12 months$18.9B-$21M
Earnings per share, 12 months$5.81-$1.01
Revenue growth, year on year8.6%216.9%
Revenue growth a year, past+5.9%over 5 years–
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVPHAT
Margins and returns on capital
Gross margin73.7%80.7%
Operating margin32.2%-9.3%
Net margin15.7%-30.2%
ROIC25.7%–
ROE––

Balance sheet

ABBVPHAT
Balance sheet
Cash$10.8B$185M
Total debt$80.9B–
Net debt / EBITDA3.2–
Interest cover7.1×-0.4×

Dividends and buybacks

ABBVPHAT
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.5%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or PHAT

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Phathom Pharmaceuticals?

By market value, AbbVie ($522B) is about 1,092.4 times Phathom Pharmaceuticals ($478M), at today's prices.

How did ABBV and PHAT stock do over the last 5 years?

Since November 12, 2021, ABBV's price moved +152.2% and PHAT's -72.2%. With dividends: ABBV +201.5% (+24.7% a year), PHAT -72.2% (-22.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or PHAT?

The dividend yield at today's price is 2.35% for AbbVie and none for Phathom Pharmaceuticals. Over the last twelve months they paid $6.92 and – per share.

Which has the higher profit margins, AbbVie or Phathom Pharmaceuticals?

Over the last twelve months, the net margin was 15.7% for AbbVie and -30.2% for Phathom Pharmaceuticals, and the operating margin 32.2% and -9.3%. Revenue was $66.0B and $275M.

Which is the better investment, AbbVie or Phathom Pharmaceuticals?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.